In this video, health-care analyst David Williamson discusses Dendreon's recent third-quarter results. He focuses on why, despite the positive trends, Dendreon is far from out of the woods. Watch and find out why investors who bid up shares as much as 30% intraday on Friday may be missing the bigger picture.
David Williamson owns shares of Johnson & Johnson. Follow him on Twitter, @MotleyDavid. The Motley Fool owns shares of Dendreon and Johnson & Johnson. Motley Fool newsletter services recommend Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
